Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent malignant glioma or metastatic brain cancer requiring craniotomy for gross total resection, subtotal resection or biopsy~* Previously histopathologically proven glioma or radiographic appearance of metastatic lesion with a primary neoplasm that is known to metastasize to the brain~* Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)~* Patients must have normal hematologic, renal and liver function (i.e. Hemoglobin \>10 gm/dl, Absolute neutrophil count ≥ 1500/mm3, Platelets ≥ 100,000/mm3, creatinine ≤ 1.5 mg/dl or Cr Clearance ≥ 60 mL/min, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 4 times above the upper limits of the institutional normal.~* Patients must be able to provide written informed consent~Exclusion Criteria:~* Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety~* Patients who are pregnant or breast-feeding~* Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)~* Allergy to 5HT-(3) receptor antagonist including tropisetron, ondansetron~* Patients on enzyme-inducing anticonvulsants (Dilantin, Tegretol, Phenobarbital)~* Patients with unstable angina or serious cardiovascular disease~* Known HIV positivity or AIDS-related illness~* History of allergic reaction to platinum compounds or mannitol~* Medical conditions requiring the use of oral nitrates~* Patients on alpha-1 adrenergic blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil + Carboplatin (Type: EXPERIMENTAL): Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
- Carboplatin Alone (Type: ACTIVE_COMPARATOR): Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).